|Print Page | Close Window|
NASDAQ | SNSS (Common Stock) $3.09 +0.02
Data provided by Nasdaq. Minimum 15 minutes delayed.
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid and hematologic cancers. Our most advanced program is QINPREZO™ (vosaroxin), our product candidate for the potential treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative, or AQD—a class of compounds that has not been used previously for the treatment of cancer. Sunesis has built a highly experienced cancer drug development organization committed to advancing vosaroxin in multiple indications to improve the lives of people with cancer.
May 08 2017Sunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights
May 01 2017Sunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) for Vosaroxin as a Treatment for Relapsed/Refractory AML
There are currently no events scheduled.